抗体

p21 Cip1抗体

MBS9607080

0.1毫升

240美元

多克隆

兔

未共轭

人类, 小鼠, 大鼠

免疫印迹, 酶联免疫吸附测定, 免疫组化, 免疫细胞化学, 酶免疫法

抗体

p21 Cip1抗体

[p21 Cip1]

[CAP20; CDK-interacting protein 1; CDKI; CDKN1; Cdkn1a; CDN1A_HUMAN; CIP1; Cyclin Dependent Kinase Inhibitor 1A; Cyclin-dependent kinase inhibitor 1; Cyclin-dependent kinase inhibitor 1A (P21); Cyclin-dependent kinase inhibitor 1A (p21, Cip1); DNA Synthesis Inhibitor; MDA-6; MDA6; Melanoma differentiation-associated protein 6; Melanoma differentiation-associated protein; p21; P21 protein; p21CIP1; p21Cip1/Waf1; p21WAF; PIC1; SDI1; SLC12A9; WAF1; Wild type p53 activated fragment 1 (WAF1); Wild type p53 activated fragment 1; Wildtype p53-activated fragment 1]

[cyclin-dependent kinase inhibitor 1 isoform 1; Cyclin-dependent kinase inhibitor 1; cyclin-dependent kinase inhibitor 1; cyclin dependent kinase inhibitor 1A; CDK-interacting protein 1; Melanoma differentiation-associated protein 6; MDA-6; p21]

[CDKN1A]

[CDKN1A;CDKN1A;P21;CIP1;SDI1;WAF1;CAP20;CDKN1;MDA-6;p21CIP1;CAP20;CDKN1;CIP1;MDA6;PIC1;SDI1;WAF1;MDA-6]

多克隆

IgG

兔

人类, 小鼠, 大鼠

164

p21 Cip1抗体检测内生水平总数p21 Cip1

The antiserum was purified by peptide affinity chromatography using SulfoLink Coupling Resin.

液体;磷酸盐缓冲液, pH值7.4, 150mM氯化钠, 0.02% 叠氮化钠和50% 甘油

1毫克/毫升

Store at -20 degree C. Stable for 12 months from date of receipt.

Western Blot (WB), Immunohistochemisty (IHC), Immunofluorescence (IF), Immunocytochemistry (ICC), ELISA (EIA)

WB: 1:500-1:2000。 IHC: 1:50-1:200。 IF/ICC: 1:100-1:500

免疫组化(免疫组化)

Immunofluorescene (IF)

免疫印迹(免疫印迹)

Immunogen: A synthesized peptide derived from human p21 Cip1. Subcellular Location: Cytoplasm. Nucleus. Tissue Specificity: Expressed in all adult tissues, with 5-fold lower levels observed in the brain.

Conjugation: Unconjugated

Description: The tumor suppressor protein p21 Waf1/Cip1 acts as an inhibitor of cell cycle progression. It functions in stoichiometric relationships forming heterotrimeric complexes with cyclins and cyclin-dependent kinases. In association with CDK2 complexes, it serves to inhibit kinase activity and block progression through G1/S (1). However, p21 may also enhance assembly and activity in complexes of CDK4 or CDK6 and cyclin D (2). The carboxy-terminal region of p21 is sufficient to bind and inhibit PCNA, a subunit of DNA polymerase, and may coordinate DNA replication with cell cycle progression (3). Upon UV damage or during cell cycle stages when cdc2/cyclin B or CDK2/cyclin A is active, p53 is phosphorylated and upregulates p21 transcription via a p53-responsive element (4). Protein levels of p21 are downregulated through ubiquitination and proteasomal degradation (5). Function: May be involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. Inhibits DNA synthesis by DNA polymerase delta by competing with POLD3 for PCNA binding (PubMed:11595739). Subunit Structure: Interacts with HDAC1; the interaction is prevented by competitive binding of C10orf90/FATS to HDAC1 facilitating acetylation and protein stabilization of CDKN1A/p21 (By similarity). Interacts with MKRN1 (PubMed:19536131). Interacts with PSMA3 (PubMed:11350925). Interacts with PCNA (PubMed:11595739, PubMed:18794347, PubMed:18703516, PubMed:8861913). Component of the ternary complex, cyclin D-CDK4-CDKN1A. Interacts (via its N-terminal domain) with CDK4; the interaction promotes the assembly of the cyclin D-CDK4 complex, its nuclear translocation and promotes the cyclin D-dependent enzyme activity of CDK4 (PubMed:9106657). Binding to CDK2 leads to CDK2/cyclin E inactivation at the G1-S phase DNA damage checkpoint, thereby arresting cells at the G1-S transition during DNA repair (PubMed:19445729). Interacts with PIM1 (PubMed:12431783). Interacts with STK11 and NUAK1 (PubMed:25329316). Post-translational Modifications: Phosphorylation of Thr-145 by Akt or of Ser-146 by PKC impairs binding to PCNA. Phosphorylation at Ser-114 by GSK3-beta enhances ubiquitination by the DCX(DTL) complex. Phosphorylation of Thr-145 by PIM2 enhances CDKN1A stability and inhibits cell proliferation. Phosphorylation of Thr-145 by PIM1 results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. UV radiation-induced phosphorylation at Thr-80 by LKB1 and at Ser-146 by NUAK1 leads to its degradation. Ubiquitinated by MKRN1; leading to polyubiquitination and 26S proteasome-dependent degradation. Ubiquitinated by the DCX(DTL) complex, also named CRL4(CDT2) complex, leading to its degradation during S phase or following UV irradiation. Ubiquitination by the DCX(DTL) complex is essential to control replication licensing and is PCNA-dependent: interacts with PCNA via its PIP-box, while the presence of the containing the 'K+4' motif in the PIP box, recruit the DCX(DTL) complex, leading to its degradation. Ubiquitination at Ser-2 leads to degradation by the proteasome pathway. Ubiquitinated by RNF114; leading to proteasomal degradation. Acetylation leads to protein stability. Acetylated in vitro on Lys-141, Lys-154, Lys-161 and Lys-163. Deacetylation by HDAC1 is prevented by competitive binding of C10orf90/FATS to HDAC1 (By similarity). Similarity: The PIP-box K+4 motif mediates both the interaction with PCNA and the recruitment of the DCX(DTL) complex: while the PIP-box interacts with PCNA, the presence of the K+4 submotif, recruits the DCX(DTL) complex, leading to its ubiquitination.The C-terminal is required for nuclear localization of the cyclin D-CDK4 complex. Belongs to the CDI family.

Hui-Fang Wang, Jing-XueMa, Qing-LiShang, Jian-BinAn, Hai-TingChen; Journal: EUR J PHARMACOL. Crocetin inhibits the proliferation, migration and TGF-beta 2-induced epithelial-mesenchymal transition of retinal pigment epithelial cells.

11386203

NP_000380.1

NM_000389.4

P38936

21 kDa

AKT Phosphorylates Targets In The Cytosol Pathway (106475); AMPK Signaling Pathway (198868); Adaptive Immune System Pathway (366160); Adipogenesis Pathway (198832); AhR Pathway (755436); Alpha6-Beta4 Integrin Signaling Pathway (198807); Androgen Receptor Signaling Pathway (198806); Angiopoietin Receptor Tie2-mediated Signaling Pathway (137917); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527)

This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-cyclin-dependent kinase2 or -cyclin-dependent kinase4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen, a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of cyclin-dependent kinase2, and may be instrumental in the execution of apoptosis following caspase activation. Mice that lack this gene have the ability to regenerate damaged or missing tissue. Multiple alternatively spliced variants have been found for this gene. [provided by RefSeq, Sep 2015]

May be involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. Inhibits DNA synthesis by DNA polymerase delta by competing with POLD3 for PCNA binding (PubMed:11595739).

0.1毫升

240美元

0.2毫升

280